Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies (MELODY)
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 Antibody Responses in Immunosuppressed People (The MELODY Study)
Sponsor: IPSOS
Listed as NCT05148806, this observational or N/A phase trial focuses on Autoimmune Diseases and Haematological Malignancies and remains completed. Sponsored by IPSOS, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Jan 2025 — Present [monthly]
Completed
-
Sep 2024 — Jan 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Feb 2023 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Jun 2022 — Feb 2023 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Mar 2022 — Jun 2022 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jan 2022 — Mar 2022 [monthly]
Not Yet Recruiting
First recorded
Dec 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- IPSOS
- Imperial College London
- NHS Blood and Transplant
- Nottingham University Hospitals NHS Trust
- University of Nottingham
For direct contact, visit the study record on ClinicalTrials.gov .